MRNA · News · 20260731N
Revenue Performance and Mix
Moderna, Inc. · 2026-07-31 · Importance 65 · Surprise 32
Moderna reported second-quarter 2026 revenue of $145 million, up 2.1% year over year and above the high end of its prior guidance range. Revenue remained heavily influenced by COVID-19 vaccine sales, while the company is targeting up to 10% revenue growth for full-year 2026. Moderna expects its flu vaccine and future COVID-flu combination to help offset declining pandemic-era vaccine demand.